vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Falcon's Beyond Global, Inc. (FBYD). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $6.6M, roughly 1.7× Falcon's Beyond Global, Inc.). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -186.0%, a 181.5% gap on every dollar of revenue. On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs 112.8%). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs 90.4%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.

CCCC vs FBYD — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.7× larger
CCCC
$11.0M
$6.6M
FBYD
Growing faster (revenue YoY)
FBYD
FBYD
+270.7% gap
FBYD
383.5%
112.8%
CCCC
Higher net margin
FBYD
FBYD
181.5% more per $
FBYD
-4.5%
-186.0%
CCCC
Faster 2-yr revenue CAGR
FBYD
FBYD
Annualised
FBYD
108.4%
90.4%
CCCC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
FBYD
FBYD
Revenue
$11.0M
$6.6M
Net Profit
$-20.5M
$-296.0K
Gross Margin
Operating Margin
-210.1%
-30.9%
Net Margin
-186.0%
-4.5%
Revenue YoY
112.8%
383.5%
Net Profit YoY
40.7%
97.5%
EPS (diluted)
$-0.09
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
FBYD
FBYD
Q4 25
$11.0M
$6.6M
Q3 25
$11.2M
$4.1M
Q2 25
$6.5M
$2.5M
Q1 25
$7.2M
$1.7M
Q4 24
$5.2M
$1.4M
Q3 24
$15.4M
$2.1M
Q2 24
$12.0M
$1.8M
Q1 24
$3.0M
$1.5M
Net Profit
CCCC
CCCC
FBYD
FBYD
Q4 25
$-20.5M
$-296.0K
Q3 25
$-32.2M
$-10.4M
Q2 25
$-26.0M
$25.1M
Q1 25
$-26.3M
$-8.1M
Q4 24
$-34.6M
$-11.9M
Q3 24
$-24.7M
$39.3M
Q2 24
$-17.7M
$8.0M
Q1 24
$-28.4M
$114.0M
Operating Margin
CCCC
CCCC
FBYD
FBYD
Q4 25
-210.1%
-30.9%
Q3 25
-306.4%
-90.9%
Q2 25
-441.0%
-53.0%
Q1 25
-402.9%
-371.1%
Q4 24
-728.4%
-335.6%
Q3 24
-183.9%
-118.9%
Q2 24
-178.6%
-195.9%
Q1 24
-1060.2%
-350.5%
Net Margin
CCCC
CCCC
FBYD
FBYD
Q4 25
-186.0%
-4.5%
Q3 25
-286.4%
-256.8%
Q2 25
-402.6%
985.2%
Q1 25
-363.7%
-473.8%
Q4 24
-667.8%
-871.7%
Q3 24
-160.6%
1899.5%
Q2 24
-147.6%
446.5%
Q1 24
-933.2%
7521.4%
EPS (diluted)
CCCC
CCCC
FBYD
FBYD
Q4 25
$-0.09
$-0.01
Q3 25
$-0.44
$-0.13
Q2 25
$-0.37
$0.30
Q1 25
$-0.37
$-0.13
Q4 24
$-0.50
$-0.25
Q3 24
$-0.35
$0.39
Q2 24
$-0.26
$0.00
Q1 24
$-0.41
$1.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
FBYD
FBYD
Cash + ST InvestmentsLiquidity on hand
$74.6M
$1.9M
Total DebtLower is stronger
$15.6M
Stockholders' EquityBook value
$256.6M
$11.9M
Total Assets
$359.1M
$66.7M
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
FBYD
FBYD
Q4 25
$74.6M
$1.9M
Q3 25
$58.8M
$4.3M
Q2 25
$78.2M
$26.1M
Q1 25
$51.3M
$1.1M
Q4 24
$55.5M
$825.0K
Q3 24
$59.6M
$828.0K
Q2 24
$73.1M
$1.7M
Q1 24
$89.7M
$1.1M
Total Debt
CCCC
CCCC
FBYD
FBYD
Q4 25
$15.6M
Q3 25
Q2 25
Q1 25
Q4 24
$41.2M
Q3 24
$10.3M
Q2 24
$15.7M
Q1 24
$15.1M
Stockholders' Equity
CCCC
CCCC
FBYD
FBYD
Q4 25
$256.6M
$11.9M
Q3 25
$154.4M
$9.2M
Q2 25
$174.1M
$414.0K
Q1 25
$195.1M
$-11.6M
Q4 24
$216.0M
$-9.0M
Q3 24
$242.7M
$-1.4M
Q2 24
$247.1M
$-44.7M
Q1 24
$258.3M
$-61.7M
Total Assets
CCCC
CCCC
FBYD
FBYD
Q4 25
$359.1M
$66.7M
Q3 25
$265.5M
$66.8M
Q2 25
$296.5M
$89.2M
Q1 25
$319.5M
$56.7M
Q4 24
$349.6M
$61.2M
Q3 24
$376.1M
$66.5M
Q2 24
$381.1M
$65.9M
Q1 24
$398.4M
$67.8M
Debt / Equity
CCCC
CCCC
FBYD
FBYD
Q4 25
1.31×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
FBYD
FBYD
Operating Cash FlowLast quarter
$-22.1M
$-4.3M
Free Cash FlowOCF − Capex
$-4.3M
FCF MarginFCF / Revenue
-66.0%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
FBYD
FBYD
Q4 25
$-22.1M
$-4.3M
Q3 25
$-31.2M
$-13.3M
Q2 25
$-12.1M
$-7.9M
Q1 25
$-33.3M
$945.0K
Q4 24
$-17.9M
$-3.8M
Q3 24
$-24.1M
$-2.4M
Q2 24
$-5.0M
$-2.6M
Q1 24
$-18.1M
$-3.8M
Free Cash Flow
CCCC
CCCC
FBYD
FBYD
Q4 25
$-4.3M
Q3 25
$-31.6M
$-13.4M
Q2 25
Q1 25
$853.0K
Q4 24
$-17.9M
$-3.8M
Q3 24
$-24.1M
$-2.4M
Q2 24
$-5.2M
$-2.6M
Q1 24
$-3.8M
FCF Margin
CCCC
CCCC
FBYD
FBYD
Q4 25
-66.0%
Q3 25
-281.5%
-329.6%
Q2 25
Q1 25
49.9%
Q4 24
-346.5%
-278.7%
Q3 24
-157.2%
-114.9%
Q2 24
-43.1%
-145.6%
Q1 24
-248.8%
Capex Intensity
CCCC
CCCC
FBYD
FBYD
Q4 25
0.3%
Q3 25
3.7%
1.0%
Q2 25
0.0%
Q1 25
5.4%
Q4 24
0.1%
0.1%
Q3 24
0.1%
0.2%
Q2 24
1.6%
0.1%
Q1 24
0.0%
0.3%
Cash Conversion
CCCC
CCCC
FBYD
FBYD
Q4 25
Q3 25
Q2 25
-0.31×
Q1 25
Q4 24
Q3 24
-0.06×
Q2 24
-0.33×
Q1 24
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons